Registration
  • Traders Union
  • All News
  • Regeneron Pharmaceuticals, Inc. (REGN) News Today: Latest Market and Industry Updates
Advertiser Disclosure

Regeneron Pharmaceuticals, Inc. (REGN) News Today: Latest Market and Industry Updates

611.05
24.5000
3.85 %
At close 06/08
USD
USD
NASDAQ
Daily range
609.11 Arrow from to Icon 633.92
Weekly range
591.52 Arrow from to Icon 640.77
Live Price Short-Term Long-Term Signals Price History News
Regeneron Pharmaceuticals stock price forecast: $588.98 support in focus as REGN slides 3.86%
  • Ashutosh Sureka
  • 7 hours ago
Regeneron Pharmaceuticals stock price forecast: $588.98 support in focus as REGN slides 3.86%
Regeneron Pharmaceuticals (REGN) stock is trading at $611.01 after losing 3.86% on the day, underperforming across key moving averages on a pronounced sell-off and ...
#Forecast
Regeneron Pharmaceuticals shares dip amid rising selling pressure
  • Sholanke Dele
  • 01.06.2026
Regeneron Pharmaceuticals shares dip amid rising selling pressure
Regeneron Pharmaceuticals (REGN) is trading well below its 20-day, 50-day, and 200-day simple moving averages, with the current price at $603.04 compared to $675.81, $719.37, and $694.72 ...
#Forecast
Regeneron Pharmaceuticals stock consolidates as Global Capability Centre opening in Hyderabad draws focus
  • Oleg Tkachenko
  • 26.05.2026
Regeneron Pharmaceuticals stock consolidates as Global Capability Centre opening in Hyderabad draws focus
Regeneron Pharmaceuticals (REGN) stock is trading at $639.22, posting a minimal daily gain of 0.09%. The price remains well below its key moving averages, indicating it ...
#Forecast
Regeneron stock price forecast: consolidation likely as REGN faces resistance below recent highs
  • Yaroslav Dmytrenko
  • 27.03.2026
Regeneron stock price forecast: consolidation likely as REGN faces resistance below recent highs
Regeneron received approval for its treatment as the first targeted medicine for certain adults with bullous pemphigoid in Japan.The company announced the news in a tweet and included a link for ...
Regeneron Pharmaceuticals gains FDA approval for allergy treatment
  • Ivan Andriyenko
  • 24.02.2026
Regeneron Pharmaceuticals gains FDA approval for allergy treatment
Regeneron Pharmaceuticals has announced that the U.S. FDA has approved its medicine for the treatment of allergic fungal rhinosinusitis (AFRS) in patients aged 6 or older. This development marks ...
Regeneron Pharmaceuticals showcases 36 breakthroughs at AAAAI26
  • Yulia Slavina
  • 10.02.2026
Regeneron Pharmaceuticals showcases 36 breakthroughs at AAAAI26
Regeneron Pharmaceuticals is showcasing their latest advances in immunology and inflammation at the AAAAI26 conference. The company is presenting 36 abstracts, including first-time Phase 3 ...
Regeneron Pharmaceuticals partners with Tessera Tx on genetic breakthrough
  • Elena Nikulina
  • 01.12.2025
Regeneron Pharmaceuticals partners with Tessera Tx on genetic breakthrough
Regeneron Pharmaceuticals has announced a significant collaboration with Tessera Therapeutics, aiming to revolutionize genomic medicine. The partnership will integrate Regeneron's expertise in ...
Regeneron Pharmaceuticals unveils new blood cancer data at ASH25
  • Ashutosh Sureka
  • 13.11.2025
Regeneron Pharmaceuticals unveils new blood cancer data at ASH25
Regeneron Pharmaceuticals has introduced new and updated findings from its hematology portfolio at ASH25. This presentation aims to highlight innovative potential approaches across a range of ...
Regeneron unveils Phase 2 data in The Lancet improving heart health
  • Ashutosh Sureka
  • 08.11.2025
Regeneron unveils Phase 2 data in The Lancet improving heart health
Regeneron Pharmaceuticals has released Phase 2 data on its novel investigational factor XI antibodies, marking a significant step in heart health research. The data was published in The Lancet and ...
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org World Association of News Publishers https://gdpr.eu/ GDPR